German medical startup BellaSeno has enrolled 30 patients across two Australian trials of a polycaprolactone breast scaffold designed to regenerate tissue without leaving a permanent foreign body. The 30 patients are spread across a first-in-human safety study that ran from 2021 to 2023 and enrolled 19 patients, and a pivotal trial launched in January 2026…